Journal
CURRENT MEDICINAL CHEMISTRY
Volume 26, Issue 26, Pages 5019-5035Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/0929867325666180904105212
Keywords
Boron; boron-containing compounds; boron-containing drugs; onychomycosis treatment; anti-cancer drugs; drug delivery; boron neutron capture therapy
Funding
- Macau University of Science and Technology [FRG-17050-SP]
- FDCT grant from the Science and Technology Development Fund of Macao [0030/2018/A1]
Ask authors/readers for more resources
Boron-containing compounds are essential micronutrients for animals and plants despite their low-level natural occurrence. They can strengthen the cell walls of the plants and they play important role in supporting bone health. However, surprisingly, boron-containing compounds are seldom found in pharmaceutical drugs. In fact, there are no inherent disadvantages reported so far in terms of the incorporation of boron into medicines. Indeed, drugs based on boron-containing compounds, such as tavaborole (marked name Kerydin) and bortezomib (trade name Velcade) have been investigated and they are used in clinical treatment. In addition, following the advanced development of boron neutron capture therapy and a new emerging proton boron fusion therapy, more boron-containing medicinals are to be expected. This review discusses the current status and perspectives of delivery strategy for boron-containing drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available